Table 1. Cannabinoids and Suppression of Autoimmune and Inflammatory Conditions.

Disease Model	Effect	Cannabinoids*	Citation
Murine Experimental Autoimmune Encephalitis (EAE)	in vivo: disease enhanced in CB2 k/o mice in vitro: JWH-133 inhibited response to the inducing antigen.	JWH-133	Maresz et al. 2007
	in vivo: resolved primary exacerbation and dampened relapses	O-1966	Zhang et al. 2009b
Murine Systemic Sclerosis	in vivo: cannabinoids ameliorated disease.	JWH-133	Akhmetshina et al 2009
	Disease enhanced in CB2 k/o mice	JWH-133	Servettaz et al 2010
Murine Colitis	in vivo: reduced symptoms. AM630, a CB2 receptor antagonist blocked beneficial effects.	JWH-133 AM1241	Storr et al 2009
Murine Inflammatory Bowel Disease	in vivo: reduced clinical scores. A CB2 receptor antagonist blocked beneficial effects.	JWH-133	Singh et al 2012
Murine Autoimmune Uveoretinitis	in vivo: inhibited T-cell infiltration into the eye by down-regulating adhesion molecules	JWH-133	Xu et al 2007
Murine Diabetes	in vivo: ameliorated disease. Both CB1 and CB2 receptors implicated.	Δ9-THC	Li et al 2001
Murine Graft Rejection	in vitro: suppressed MLR proliferative response.	O-1966	Robinson et al 2013

^*Δ⁹-THC activates CB1 and CB2 receptors. JWH-133, O-1966 and AM1241 are CB2 selective.